Studies on Activity of NK Cells in Preeclampsia Patients

The activity of the NK cells in patients with preeclampsia was studied to investigate the pathogenesis of preeclampsia. By using MTT and 51Cr releasing technique, the proliferation and killing ability of the NK cells in maternal and umbilical blood from preeclampsia patients (n=18) and normal third trimester pregnant women (n=18) were detected. The NK-92 cell line was as the positive control. The results showed that the NK cell counts of umbilical blood in preeclampsia patients and normal third trimester pregnant women were significantly greater than those of maternal blood (both P<0.05). Compared with that in normal third trimester pregnant women, the proliferative ability of the NK cells in preeclampsia patients was apparently increased (P<0.05). Compared with that in maternal blood, the proliferative ability of the NK cells in umbilical blood from both preeclampsia patients and normal third trimester pregnant women was dramatically increased. The killing ability of the NK cells in preeclampsia patients was significantly higher than that in normal third trimester pregnant women (P <0.05). It was suggested that both number and function of the NK cells in preeclampsia women were increased, and that in umbilical blood was greater than that in maternal blood, speculating that the function of the NK cells may affect the maintenance of the maternal and fetal immune tolerance during pregnancy.

参芪扶正对肝癌化疗血浆免疫蛋白表达的影响及疗效观察

研究参芪扶正注射液对肝癌化疗患者免疫功能的影响及疗效观察。方法：132例原发性肝癌患者随机分为对照组和观察组，对照组患者给予动脉栓塞化疗，观察组患者在动脉栓塞化疗基础上静脉注射液参芪扶正注射液。分别于治疗前和疗程结束后，采用免疫散射比浊法测定患者外周血免疫球蛋白A（immunoglobulin，IgA）、G和M蛋白含量，流式细胞仪测定CD3、CD4＋、CDs细胞亚群数量，”CT释放法测定自然杀伤细胞（naturekill，NK）的活性；疗程结束后，采用RECIST1．1标准评价患者近期疗效，统计总有效率（RR）；治疗结束后每3个月进行随访1次，统计患者的2年无病生存率。于治疗前和治疗后，采用Karnofsky评分为标准评定患者生活质量改善情况，统计总改善率。结果：观察组患者淋巴细胞亚群CD3＋、CD4＋、CD4＋／cD8＋水平及NK细胞活性较治疗前和对照组显著升高（P〈0．05），CDs细胞水平显著降低（P〈0．05）；而对照组治疗后含量与治疗前差异无统计学意义（P〉0．05）。观察组总有效率显著高于对照组（80．65％VS56．45％，X2=4．308，P=0．038〈0．05）。观察组中位生存期为19．10个月（95％CI：15．418—22．782），对照组中位生存期为11．20个月（95％CI：9．71～12．294），差异有统计学意义（P〈0．05）。观察组患者生活质量总改善率显著高于对照组（85．48％VS51．6l％，）（X2=4．308，P=〈0．001）。且观察组白细胞减少、血红蛋白减少和血小板减少III—IV级不良反应发生率显著低于对照组（P〈0．05）。结论：参芪扶正注射液可以显著改善肝癌化疗患者免疫功能，提高患者预后，降低不良反应发生率。